我国已上市新型抗凝药物的特点及临床应用进展  

Characteristics of novel anticoagulants marketed in China and the development of their clinical application

作　　者：尤国皎 都丽萍[1] 陈跃鑫[2] 梅丹[1] 

机构地区：[1]中国医学科学院北京协和医学院协和医院药剂科,北京100730 [2]中国医学科学院北京协和医学院协和医院血管外科,北京100730

出　　处：《临床药物治疗杂志》2017年第1期1-7,共7页Clinical Medication Journal

基　　金：国家自然科学基金项目(81300235);北京药学会2016年临床药学基金项目

摘　　要：目的:为临床规范化使用新型抗凝药物提供借鉴。方法:复习有关新型抗凝药的药物特点,结合临床试验结果,解读抗凝、抗栓治疗指南的更新要点。结果:传统抗凝药肝素、低分子肝素、华法林抗栓效果明确、可靠,但这些药物仍存在各自的不足。相比之下,新型抗凝药物具有药代动力学稳定、可固定剂量使用、与药物及食物等相互作用少、药物安全性良好等突出优点。结论:新型抗凝药可较大程度上弥补传统药物的缺陷,为血栓栓塞性疾病、房颤及房颤合并冠心病患者带来了新的希望。Objective： To provide references for the clinical use of new anticoagulants. Methods： The characteristics of new anticoagulants were reviewed, clinical trial results were referred, and the update antithrombotic therapy guidelines were interpreted. Results： The effects of traditional anticoagulants （heparin, low molecular weight heparin and warfarin） are clear and reliable, but these drugs still have their own drawbacks. In contrast, new anticoagulants have more stable pharmacokinetic properties and fewer drug-drug/ food interactions, which make them safer and more convenient. Conclusion： New anticoagulants show more advantages compared with the traditional anticoagulants, and have brought new choices for the treatments of thromboembolic disease, atrial fibrillation and coronary heart disease.

关 键 词：新型抗凝药 临床应用 个体化用药 

分 类 号：R973.2[医药卫生—药品]